Charles River Laboratories International (CRL) Automation Push Puts Valuation Back In Focus

Charles River Laboratories International (CRL) just put its Endosafe Cartridge Technology Automated Manufacturing Suite into full swing, with automation now driving tighter endotoxin testing controls, higher cartridge output, and more consistent quality for customers.

For context, Charles River Laboratories International trades at US$272.88, and while the share price slipped around 2.6% over the past month, it has logged a strong 49.6% 90 day share price return and an 80.0% 1 year total shareholder return. This points to momentum that long term holders have not consistently enjoyed over five years.

Scan automation-driven quality stories such as Charles River Laboratories International against a curated list of resilient compounders by checking the 11 resilient stocks with low risk scores in just a few minutes.

After an 80% 1 year total return and new investment in automation, Charles River Laboratories International now poses a simple question for new capital: does the current price still offer enough potential reward relative to the risk involved?

Most Popular Narrative: 18% Overvalued

Analysts following Charles River Laboratories International see a fair value of about $230.93, which sits below the recent $272.88 close and frames the current automation push against expectations for a more expensive stock than their models support.

The company's ongoing diversification and enhancement of its capabilities through investments in new approach methodologies (NAMs), automation, and digitalization, positions it to benefit from industry shifts toward more complex and high-value testing, while also mitigating risks from regulatory and client preferences away from animal testing, improving operational efficiency and supporting future margin stability.

See why 4 investors see Charles River Laboratories International as 18% overvalued.

Result: Fair Value of $230.93 (OVERVALUED)

Still, Charles River Laboratories International faces real pressure if demand softness in longer post IND studies persists or if clients accelerate a shift toward non animal testing methods.

Find out about the key risks to this Charles River Laboratories International narrative.

Another View on Charles River Laboratories International Valuation

Analysts see Charles River Laboratories International as roughly 18% above their US$230.93 fair value marker, yet Simply Wall St's DCF model points the other way, with an estimated future cash flow value of about US$300.23. That gap suggests one simple question: Which set of assumptions do you trust more?

Look into how the SWS DCF model arrives at its fair value.

Next Steps

If the mixed signals on Charles River Laboratories International leave you undecided, act while the data is fresh and test the thesis yourself. Start by weighing the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Charles River Laboratories International?

Do not stop your research with Charles River Laboratories International. A few minutes with the right screeners can surface opportunities you might otherwise never spot.

• Target stronger downside protection by filtering for companies with robust cash and debt profiles using the list of solid balance sheet and fundamentals (22 results).
• Hunt for quality at a fair price by scanning companies that screen as potentially mispriced through the 34 high quality undervalued stocks.
• Spot future favourites early by reviewing financially sound businesses that attract less attention through the 16 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com